Allurion Technologies (ALUR) Registration Filing summary

Company overview and business model

• Focuses on a weight loss platform targeting the global obesity epidemic, offering a swallowable, procedureless intragastric balloon and an AI-powered virtual care suite for remote monitoring and behavioral support.

• Commercially treated over 150,000 patients in 50+ countries, primarily outside the U.S., with a direct sales force and distributor model.

• The platform integrates digital tools, telehealth, and AI coaching, and has expanded to include weight loss medications and bundled offerings with Medtronic.

• Holds a significant portfolio of patents related to its balloon device and supporting technologies, with ongoing expansion of IP assets.

Financial performance and metrics

• As of November 18, 2024, public float was approximately $37.1 million, with 64,486,517 shares outstanding and a recent share price of $0.77.

• The last quoted sale price on December 9, 2024, was $0.38 per share.

• Most revenue to date has come from sales of the Allurion Balloon, with initial European sales beginning in 2016.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital, operating expenses, debt repayment/refinancing, strategic acquisitions, and capital expenditures.

• Management retains broad discretion over allocation, with proceeds to be invested in short-term, interest-bearing instruments pending use.